ERBB2 and metastatic neoplasm: The results illustrated that the VLP-based vaccine candidate efficiently primed the development of HER2-sepcific antibodies, as well as effector and memory T cells, which contributed to delayed onset and progression of both primary and metastatic tumors, resulting in prolonged survival.